TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06057025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sputnik Lite vaccine for the prevention of COVID-19 with altered antigenic composition
Description: Single intramuscular injection of Sputnik Lite vaccine for the prevention of COVID-19 with altered antigenic composition.
Study: NCT06241456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT825
Description: FT825 will be administered as an intravenous (IV) infusion at planned dose levels.
Study: NCT05085756

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Puma
Description: One psychoeducation module followed by two transdiagnostic modules tailored to primary depression or anxiety symptoms, followed by three participant-choice modules, and ending with two transdiagnostic modules.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Puma
Description: One psychoeducation module followed by two transdiagnostic modules tailored to primary depression or anxiety symptoms, followed by three participant-choice modules, and ending with two transdiagnostic modules.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Puma
Description: One psychoeducation module followed by two transdiagnostic modules tailored to primary depression or anxiety symptoms, followed by three participant-choice modules, and ending with two transdiagnostic modules.
Study: NCT06260098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga with High Breath work & meditation; Low movement/postures
Description: Participants will engage in an 8 week asynchronous yoga class focused on the internal and cognitive experience within the practice using breathing and meditation focused techniques.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga with Low Breath work & meditation; High movement/postures
Description: Participants will engage in an 8 week asynchronous yoga class with a emphasis on the physicality and movements of the practice.
Study: NCT04916769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib capsule
Description: 500 mg dose of bosutinib capsule contents mixed with applesauce

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib capsule
Description: 500 mg dose of bosutinib capsule contents mixed with yogurt

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosutinib capsule
Description: 500 mg dose of intact bosutinib capsules
Study: NCT05879835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KiteLock 4% Sterile Catheter Lock Solution
Description: KiteLock™ is a clear, colorless, and sterile 4% (40 mg/ml) tetrasodium EDTA solution that contains no preservatives, latex, antibiotics, or ethanol and is nonpyrogenic. Tetrasodium salt of EDTA has been shown to disrupt in vivo and ex vivo-generated biofilms by destabilizing the structural integrity of micro-organisms at the cellular level.
Study: NCT05879835

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Lock Solution
Description: Nonpyrogenic, hypertonic preparation of heparin sodium injection, USP with sodium chloride in water for injection.
Study: NCT06241456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered as an IV infusion at planned dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered as an IV infusion at planned dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as an IV infusion at planned dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as an IV infusion at planned dose levels.
Study: NCT05417217

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discontinued ventilation
Description: Ventilation is discontinued after going on CPB and lungs are exposed to atmospheric pressure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continued ventilation
Description: Ventilation is continued from going on CPB until clamping of the ascending aorta with tidal volume 3ml/kg ideal body weight, Fraction of inspired oxygen (FiO2) 50%, respiratory rate 5/min and Inspiratory:Expiratory (I/E) ratio 1/2.
Study: NCT05736198

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: dexmedetomidine, midazolam, and fentanyl (titrated to effect) to facilitate intubation
Study: NCT05633693

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Counterpressure Maneuvers
Description: Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating two clinically recommended isometric maneuvers (crouching, and leg crossing with muscle tensing) and two novel dynamic maneuvers that comprise discrete movement that the investigators have identified in prior work (exaggerated anterior-posterior postural sway, rhythmic gluteal clenching).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counterpressure Maneuvers
Description: Movements that can aid in delaying or preventing syncope by recruiting skeletal muscle pumping (via compression of major veins by contracting muscle to eject blood through cardiovascular circuit) and increased sympathetic drive (via sustaining an isometric muscle contraction). In this trial, we will be evaluating two clinically recommended isometric maneuvers (crouching, and leg crossing with muscle tensing) and two novel dynamic maneuvers that comprise discrete movement that the investigators have identified in prior work (exaggerated anterior-posterior postural sway, rhythmic gluteal clenching).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Baseline Stand
Description: Participants will stand quietly for 5-minutes on a force platform to allow the investigators to assess their typical response to orthostasis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline Stand
Description: Participants will stand quietly for 5-minutes on a force platform to allow the investigators to assess their typical response to orthostasis.
Study: NCT06299839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAS-004 Capsules
Description: A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 1 mg, 4mg, and 10 mg strength capsules, intended for oral administration once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAS-004 Tablets
Description: A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 4mg strength tablets, intended for oral administration once daily.
Study: NCT06051591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food FARMacia Program
Description: Twice monthly delivery of groceries with about 12 meals per household member for up to 4 household members for 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed meal preparation support
Description: Nutrition education and anticipatory guidance to support healthy meal preparation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-directed meal preparation support
Description: Nutrition education and anticipatory guidance to support healthy meal preparation
Study: NCT06330051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: improvement acute reperfusion treatment quality for stroke through spatiotemporal computing
Description: 1. Intelligent bracelet automatic positioning device and data feedback system based on spatiotemporal computing technology~2. Continuous in-hospital procedure improvement based on P-D-C-A cycle for AIS
Study: NCT06490731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients will receive dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: patients Will receive ketamine
Study: NCT05995002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anthocyanin-rich diet
Description: A weekly food plan aims to increase the consumption of anthocyanin-rich sources such as berries, black grapes (or currants), cherries, strawberries, pomegranates, and red onions.
Study: NCT04305678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab (Nucala) 400 mg SC every 4 weeks x 24 weeks
Study: NCT05921604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen 10mg
Description: which will include 50 patients scheduled for sleeve gastrectomy and will receive 10 mg oral baclofen 1 h before anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: which include 50 patients scheduled for sleeve gastrectomy and will receive 600 mg oral gabapentin 1 h before anesthesia.
Study: NCT06648798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Limber Limb
Description: Participants will be involved for two months using a non-inferiority design in which the participant will be assessed using their normal device (1 month) and the study device (1 month).
Study: NCT06153316

Intervention type: OTHER
Intervention: School shooting incident
Description: The school has experienced a gun shooting incident within the past 2 years of the study (for 3 case schools) and prior to 2 years (for 3 case schools). Incidents where a gun was displayed but no shot was fired, or where a shot was fired by police or security officer will not be included.
Study: NCT05270213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBS2418
Description: RBS2418 is a potent and selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1). RBS2418 as monotherapy potentially can have an activating effect on the anti-tumor innate immune response and lead to anti-tumor responses in adult subjects with advanced or metastatic tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBS2418
Description: RBS2418 is a potent and selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1). RBS2418 as monotherapy potentially can have an activating effect on the anti-tumor innate immune response and lead to anti-tumor responses in adult subjects with advanced or metastatic tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBS2418
Description: RBS2418 is a potent and selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1). RBS2418 as monotherapy potentially can have an activating effect on the anti-tumor innate immune response and lead to anti-tumor responses in adult subjects with advanced or metastatic tumors.
Study: NCT04886284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: Adjunctive ertapenem

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo
Study: NCT05959486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR6002A
Description: One tablet administered alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR6002B
Description: One tablet administered alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR6002
Description: One capsule administered alone
Study: NCT05920954

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP
Description: Repeat ERCP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP
Description: Repeat ERCP
Study: NCT05454085

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bisphenol-A
Description: measurement of BPA levels in maternal blood and amniotic fluid
Study: NCT02831335

Intervention type: OTHER
Intervention: MRI
Description: Perform MRI studies

Intervention type: OTHER
Intervention: MRI
Description: Perform MRI studies

Intervention type: OTHER
Intervention: MRI
Description: Perform MRI studies

Intervention type: OTHER
Intervention: Group 4
Description: Perform MRI studies
Study: NCT05833139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631
Description: BI 1810631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole
Study: NCT04845685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: A device that measures blood sugar levels every 1-5 minutes
Study: NCT05130281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maya mobile app
Description: The Maya app teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maya mobile app
Description: The Maya app teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maya mobile app
Description: The Maya app teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: Participants earn points and badges for completing sessions, homework, and skills on time and receive post session feedback via text message. Participants can identify a person they know to receive updates about their progress and support them throughout their time in the program. Participants will not be required to choose a person they know to receive updates about their use of the program; instead, they can choose to have a member of the study team serve as their social support if they are assigned to this condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain Framed
Description: Participants earn points and badges for completing sessions, homework, and skills on time and receive post session feedback via text message.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss Framed
Description: Participants lost points and badges for not completing sessions, homework, and skills on time and receive post session feedback via text message.
Study: NCT06311734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LW231 tablets
Description: P.O.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LW231 tablets
Description: P.O.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LW231 tablets
Description: P.O.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: P.O.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: P.O.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: P.O.
Study: NCT05283629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuroplasticity-based Computerized Cognitive Remediation
Description: Behavioral: Neuroplasticity-based Computerized Cognitive Remediation The nCCR has two major components: Bottom up and Top down training.~* Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~* Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Control Condition
Description: The education control condition is a learning-based approach that utilizes DVDs on history, art, science, etc. This active condition is comparable to nCCR in length of exposure, audio-visual presentation, computer use and contact with research staff.
Study: NCT06039384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099280
Description: Administered as specified in the treatment arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099280
Description: Administered as specified in the treatment arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adagrasib
Description: Administered as specified in the treatment arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adagrasib
Description: Administered as specified in the treatment arm description
Study: NCT05868044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRIMUS
Description: PRIMUS system
Study: NCT05725668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dual-task tai ji quan
Description: dual-task tai ji quan training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard tai ji quan
Description: standard tai ji quan training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stretching
Description: stretching exercise
Study: NCT04932512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION224
Description: ION224 will be administered by SC injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ION224-matching placebo solution will be administered by SC injection.
Study: NCT06324630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Produce Prescription Delivery
Description: Fruit and vegetable box delivery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Meal Kit Delivery
Description: Ingredients to cook healthy meals delivered to home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Produce Prescription Mobile Market
Description: Voucher to purchase fruits and vegetables at a mobile market
Study: NCT05273996

Intervention type: DRUG
Group type: OTHER
Intervention: Sertraline, bupropion, desvenlafaxine
Description: Study geriatric psychiatrists prescribe FDA-approved antidepressants using a treatment algorithm consistent with the STAGED (Duke Somatic Treatment Algorithm for Geriatric Depression) approach, with standardization of treatment in the first six months beginning with sertraline, with the option of augmentation with bupropion or switch to desvenlafaxine. Beyond six months of acute treatment, subjects are treated based on the study psychiatrist's clinical assessment and recommendations, consistent with STAGED guidelines.
Study: NCT06509334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYB1904
Description: Participants will receive JYB1904 at week0 and receive placebo at week4,8,12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYB1904
Description: Participants will receive JYB1904 at week0,8 and receive placebo at week4,12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Participants will receive Omalizumab every 4 weeks for 12 weeks
Study: NCT05455385

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard 12-week rehabilitation program
Description: The standard program consisted of 1 session in the fitness room and 1 session in the sports hall/week during 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard 12-week rehabilitation program
Description: The standard program consisted of 1 session in the fitness room and 1 session in the sports hall/week during 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard 12-week rehabilitation program
Description: The standard program consisted of 1 session in the fitness room and 1 session in the sports hall/week during 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: extra session hydrotherapy
Description: The hydrotherapy group receives 1.5h additional hydrotherapy/week in addition to the standard program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: extra session ground exercises
Description: The ground exercise group, receives 1.5h ground exercises/week in addition to the standard program.
Study: NCT06529042

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT05268055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sign Here training intervention
Description: Training film to educate healthcare providers to competently and sensitively interact with Deaf patients in healthcare settings.

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention as usual
Description: Communicating with People Who Are Deaf or Hard of Hearing in Hospital Settings (https://archive.ada.gov/hospcombrprt.pdf)
Study: NCT06596005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ0113
Description: 200 mg or 400 mg Capsule, Once Daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, Once Daily
Study: NCT06660550

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic inguinal hernia repair
Description: traditional laparoscopic repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needlescopic inguinal hernia repair
Description: Needlescopic inguinal hernia repair
Study: NCT06661850

Intervention type: PROCEDURE
Intervention: Fusion or TDR determined by investigator.
Description: The surgical treatment will be decided by the treating investigator based on their clinical judgement.

Intervention type: PROCEDURE
Intervention: Fusion or TDR determined by investigator.
Description: The surgical treatment will be decided by the treating investigator based on their clinical judgement.
Study: NCT05633797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibriCheck
Description: During the patient's intensive care unit (ICU) stay, they will be monitored constantly to detect atrial fibrillation (standard care). After ICU dismissal, patients will be monitored using the FibriCheck application to detect atrial fibrillation until 30 days postoperative. Patients need to use the FibriCheck application for a minimum of 3x/day and can perform extra measurements when symptoms are present.
Study: NCT06589830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL938 Capsules
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL938 Capsules
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Intravenous (IV) infusion
Study: NCT06235281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mogamulizumab-Kpkc
Description: Participants will receive 8 total cycles of Mogamulizumab-Kpkc over approximately 224 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Participants will begin receiving Phototherapy on day 56 and will continue until day 224. Participants with Complete response (CR) or Partial response (PR) to therapy at day 224 will remain on phototherapy maintenance.
Study: NCT06668181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab will be administered at pre-specified timepoints.
Study: NCT05961059

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.5 μg InvaplexAR-Detox
Description: 2.5 μg intramuscular dose of Sfl2a InvaplexAR-Detox.